Journal of the American Society of Hypertension
Volume 1, Issue 6 , Pages 407-413 , November 2007

C-reactive protein and target organ damage in untreated patients with primary hypertension

Received 19 July 2007 ,Accepted 8 September 2007.

References 

  1. Libby P. Inflammation in atherosclerosis. Nature. 2002;420:868–874
  2. Danesh J, Whincup P, Walker M, Lennon L, Thomson A, Appleby P, et al. Low grade inflammation and coronary heart disease: prospective study and updated meta–analyses. BMJ. 2000;321:199–204
  3. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004;350:1387–1397
  4. Cook NR, Buring JE, Ridker PM. The effect of including C-reactive protein in cardiovascular risk prediction models for women. Ann Intern Med. 2006;145:21–29
  5. Koenig W, Lowel H, Baumert J, Meisinger C. C-reactive protein modulates risk prediction based on the Framingham Score: implications for future risk assessment: results from a large cohort study in Southern Germany. Circulation. 2004;109:1349–1353
  6. Devereux RB, Alderman MH. Role of preclinical cardiovascular disease in the evolution from risk factor exposure to development of morbid events. Circulation. 1993;88:1444–1455
  7. Pontremoli R, Sofia A, Ravera M, Nicolella C, Viazzi F, Tirotta A, et al. Prevalence and clinical correlates of microalbuminuria in essential hypertension: the MAGIC Study (Microalbuminuria: A Genoa Investigation on Complications). Hypertension. 1997;30:1135–1143
  8. Tracy RP, Psaty BM, Macy E, Bovill EG, Cushman M, Cornell ES, et al. Lifetime smoking exposure affects the association of C–reactive protein with cardiovascular disease risk factors and subclinical disease in healthy elderly subjects. Arterioscler Thromb Vasc Biol. 1997;17:2167–2176
  9. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low–density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499–502
  10. Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, et al. Recommendations for quantitation of the left ventricle by two–dimensional echocardiography (American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two–Dimensional Echocardiograms). J Am Soc Echocardiogr. 1989;2:358–367
  11. de Simone G, Devereux RB, Daniels SR, Koren MJ, Meyer RA, Laragh JH. Effect of growth on variability of left ventricular mass: assessment of allometric signals in adults and children and their capacity to predict cardiovascular risk. J Am Coll Cardiol. 1995;25:1056–1062
  12. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). [Erratum in: 2007;25:1749] J Hypertens. 2007;25:1105–1187
  13. Wendelhag I, Wiklund O, Wikstrand J. Atherosclerotic changes in the femoral and carotid arteries in familial hypercholesterolemia (Ultrasonographic assessment of intima–media thickness and plaque occurrence). Arterioscler Thromb. 1993;13:1404–1411
  14. Leoncini G, Ratto E, Viazzi F, Vaccaro V, Parodi A, Falqui V, et al. Increased ambulatory arterial stiffness index is associated with target organ damage in primary hypertension. Hypertension. 2006;48:397–403
  15. Schillaci G, Pirro M. C–reactive protein in hypertension: clinical significance and predictive value. Nutr Metab Cardiovasc Dis. 2006;16:500–508
  16. King DE, Egan BM, Mainous AG, Geesey ME. Elevation of C–reactive protein in people with prehypertension. J Clin Hypertens. 2004;6:562–568
  17. Chrysohoou C, Pitsavos C, Panagiotakos DB, Skoumas J, Stefanadis C. Association between prehypertension status and inflammatory markers related to atherosclerotic disease: the ATTICA Study. Am J Hypertens. 2004;17:568–573
  18. Sesso HD, Buring JE, Rifai N, Blake GJ, Gaziano JM, Ridker PM. C–reactive protein and the risk of developing hypertension. JAMA. 2003;290:2945–2951
  19. Schillaci G, Pirro M, Gemelli F, Pasqualini L, Vaudo G, Marchesi S, et al. Increased C–reactive protein concentrations in never–treated hypertension: the role of systolic and pulse pressures. J Hypertens. 2003;21:1841–1846
  20. Chobanian AV, Alexander RW. Exacerbation of atherosclerosis by hypertension (Potential mechanisms and clinical implications). Arch Intern Med. 1996;156:1952–1956
  21. Intengan HD, Schiffrin EL. Vascular remodeling in hypertension: roles of apoptosis, inflammation, and fibrosis. Hypertension. 2001;38:581–587
  22. Blake GJ, Rifai N, Buring JE, Ridker PM. Blood pressure, C-reactive protein, and risk of future cardiovascular events. Circulation. 2003;108:2993–2999
  23. Olsen MH, Christensen MK, Hansen TW, Gustafsson F, Rasmussen S, Wachtell K, et al. High-sensitivity C–reactive protein is only weakly related to cardiovascular damage after adjustment for traditional cardiovascular risk factors. J Hypertens. 2006;24:655–661
  24. Palmieri V, Tracy RP, Roman MJ, Liu JE, Best LG, Bella JN, et al. Strong Heart Study (Relation of left ventricular hypertrophy to inflammation and albuminuria in adults with type 2 diabetes: the strong heart study). Diabetes Care. 2003;26:2764–2769
  25. Tsioufis C, Stougiannos P, Kakkavas A, Toutouza M, Mariolis A, Vlasseros I, et al. Relation of left ventricular concentric remodeling to levels of C-reactive protein and serum amyloid A in patients with essential hypertension. Am J Cardiol. 2005;96:252–256
  26. Tsioufis C, Dimitriadis K, Chatzis D, Vasiliadou C, Tousoulis D, Papademetriou V, et al. Relation of microalbuminuria to adiponectin and augmented C-reactive protein levels in men with essential hypertension. Am J Cardiol. 2005;96:946–951
  27. Tsioufis C, Dimitriadis K, Taxiarchou E, Vasiliadou C, Chartzoulakis G, Tousoulis D, et al. Diverse associations of microalbuminuria with C-reactive protein, interleukin–18 and soluble CD 40 ligand in male essential hypertensive subjects. Am J Hypertens. 2006;19:462–466
  28. Hashimoto H, Kitagawa K, Hougaku H, Etani H, Hori M. Relationship between C-reactive protein and progression of early carotid atherosclerosis in hypertensive subjects. Stroke. 2004;35:1625–1630
  29. Verma S, Devaraj S, Jialal I. Is C-reactive protein an innocent bystander or proatherogenic culprit? (C-reactive protein promotes atherothrombosis). Circulation. 2006;113:2135–2150
  30. Mahmud A, Feely J. Arterial stiffness is related to systemic inflammation in essential hypertension. Hypertension. 2005;46:1118–1122
  31. Miller M, Zhan M, Havas S. High attributable risk of elevated C-reactive protein level to conventional coronary heart disease risk factors: the Third National Health and Nutrition Examination Survey. Arch Intern Med. 2005;165:2063–2068
  32. Albert MA, Glynn RJ, Ridker PM. Plasma concentration of C–reactive protein and the calculated Framingham Coronary Heart Disease Risk Score. Circulation. 2003;108:161–165

 Conflict of interest: none.

PII: S1933-1711(07)00198-2

doi: 10.1016/j.jash.2007.09.003

Journal of the American Society of Hypertension
Volume 1, Issue 6 , Pages 407-413 , November 2007

Article Tools

* Image Usage & Resolution